Lupus Insight Hub

Putting yourself first may directly support autoimmune health, including lupus. Research shows women raised as eldest or only daughters—who often...

Climb Bio announced initial Phase 1b data on budoprutug, now under evaluation in trials for systemic lupus erythematosus (SLE) as well as pMN and immune thrombocytopenia. A subcutaneous formulation is also advancing.

A UCL-led Phase I trial of Autolus' obe-cel CAR T therapy delivered striking results for treatment-resistant lupus patients. One participant, Katie...

Precision medicine will shape the future of lupus treatment through an 'N of One' approach, says Lupus Research Alliance president Albert T. Roy.

Astragaloside IV (AS-IV), a natural compound, alleviates lupus nephritis in preclinical models by inhibiting podocyte ferroptosis through the...

A narrative review positions thalidomide and lenalidomide as targeted options for refractory cutaneous lupus erythematosus in patients failing standard therapies.

A 2026 review by KA Kirou examines new and emerging lupus treatments developed in recent years and their potential to shape fresh directions in disease management.

NHS CAR-T Immune Reset Trial

• 🔥 Remission Achieved: Five of six severe lupus patients in a UCLH/UCL NHS trial achieved remission within months...

• Katie Tinkler, diagnosed 30 years ago, is now medication-free and skiing after treatment
• Engineered T-cells destroy rogue B cells to reset the...

Large language models are emerging as valuable tools in SLE care, enhancing both patient education and clinical decision support per EULAR 2026...

TYK2 inhibitors such as deucravacitinib are advancing as a potential new oral therapy for SLE by targeting IL-12, IL-23, and type 1 interferons with a...

Clinical Trial Updates

• 🔥 Sirolimus Add-On Therapy: EULAR 2026 randomized trial supports sirolimus given in addition to standard therapy for...

Cullinan is advancing two T cell engager candidates for SLE with distinct targets.

• CLN-978 (CD19xCD3): Early data show immune reset potential and...

A phase 1 trial provides extended follow-up on BCMA-CD19 armored CAR T cells in systemic lupus erythematosus, highlighting durability and immune reset potential.

A randomized trial presented at EULAR 2026 found sirolimus effective as add-on therapy for active, uncontrolled systemic lupus erythematosus when combined with standard treatment.

The lupus nephritis clinical trial landscape now includes 35+ pipeline drugs under active investigation, with fresh analysis highlighting evolving clinical strategies and research approaches.

Litifilimab shows early promise for cutaneous lupus erythematosus, delivering improved CLASI-A scores in treated patients. This could help address a key treatment gap.

Correcting magnesium deficiency—common in men with lupus from dietary limits or medication effects—may subtly aid erectile dysfunction management.

A $2.5 million Colton Foundation gift will expand Yale's Colton Center for Autoimmunity, supporting faculty recruitment, innovative projects, and...

Lupus Colorado warns that Most Favored Nation drug pricing threatens timely access for patients who cannot wait for treatment.

• Rapid disease...